Global Vaccine and Immunization Research Forum

RSV vaccine development for Low and Middle Income Countries: Challenges and Progress

Claudio F. Lanata, MD, MPH
Senior Researcher,
Instituto de Investigación Nutricional – IIN;
Science Director,
US Naval Medical Research Unit No 6 – NAMRU 6;
Professor,
Universidad Peruana de Ciencias Aplicadas – UPC;
Lima, Perú
Disclaimer

The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government.
Global causes of child deaths

- Pneumonia: 14%
- Preterm birth complications: 12%
- Birth asphyxia: 9%
- Sepsis: 6%
- Other: 5%
- Congenital abnormalities: 3%
- Tetanus: 1%
- Diarrhoea: 1%
- Malaria: 8%
- Injury: 3%
- Measles: 1%
- AIDS: 2%
- Pertussis: 2%
- Other non-communicable diseases: 4%

Neonatal deaths: 41%
Burden of RSV in the world

• Systematic review of studies published 1995-2009
  • For 2005:
    – 33.8 (95% CI 19.3-46.2) million RSV cases in children <5
    – 96% in developing countries
    – 3.4 million severe RSV cases, 91% in developing countries

• Case fatality in RSV severe ALRI
  – 0.3% in children <5 y in developed countries
  – 2.1% in children <5 in developing countries

• Global mortality estimates in children <5 global:
  – 65,590 deaths, 99% in developing countries by CFR method
  – 155,232 deaths in dev countries by hypoxaemia method
  – 199,260 deaths in dev countries extrapolating from Indonesia study

RSV as caused of Severe Acute Lower Respiratory Infections in the World

- Estimated burden of pneumonia and applied etiological fractions, adjusted for Hib and Strep pneumo vaccine use, with models applied for each country in the world.
- RSV burden:
  - 29% of all ALRI
  - 23% of all severe ALRI
- 3.2 million cases of RSV severe ALRI in children <5 y in the world in 2010 (95% CI: 1.7-6.1 million):
  - SEARO 38%
  - AFRO 17%
  - AMRO 13%
  - WPRO 13%
  - EMRO 11%
  - EURO 8%
- No mortality estimates

Ref: Rudan I et al. J Glob Health 2013;3:010401
Ubicacion geografica del estudio
<table>
<thead>
<tr>
<th>Virus</th>
<th>Incidence (95% CI)</th>
<th>All ages</th>
<th>0 - 5 months</th>
<th>6 - 11 months</th>
<th>12 - 35 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human rhinovirus</td>
<td></td>
<td>236 (221 - 252)</td>
<td>266 (234 - 303)</td>
<td>313 (280 - 351)</td>
<td>206 (190 - 224)</td>
</tr>
<tr>
<td>Adenovirus</td>
<td></td>
<td>73 (65 - 82)</td>
<td>27 (19 - 38)</td>
<td>99 (78 - 125)</td>
<td>81 (71 - 93)</td>
</tr>
<tr>
<td>Parainfluenza 1-3</td>
<td></td>
<td>46 (41 - 51)</td>
<td>41 (31 - 53)</td>
<td>54 (43 - 68)</td>
<td>45 (39 - 51)</td>
</tr>
<tr>
<td>Influenza</td>
<td></td>
<td>37 (31 - 43)</td>
<td>35 (26 - 48)</td>
<td>44 (34 - 57)</td>
<td>31 (27 - 37)</td>
</tr>
<tr>
<td>Respiratory syncytial virus</td>
<td></td>
<td>30 (26 - 34)</td>
<td>34 (25 - 47)</td>
<td>34 (25 - 45)</td>
<td>28 (23 - 33)</td>
</tr>
<tr>
<td>Human metapneumovirus</td>
<td></td>
<td>17 (14 - 20)</td>
<td>12 (8 - 20)</td>
<td>27 (19 - 37)</td>
<td>16 (13 - 20)</td>
</tr>
<tr>
<td>Any one of the above viruses</td>
<td></td>
<td>360 (340 - 380)</td>
<td>365 (327 - 409)</td>
<td>472 (430 - 518)</td>
<td>328 (306 - 352)</td>
</tr>
</tbody>
</table>

Causes of ARI and Severe ARI in children <3 in San Marcos, Cajamarca, Peru

RSV and metapneumovirus

Figure 1. Study site and location of all severe acute respiratory infection cases, Matlab, Bangladesh-2010.
doi:10.1371/journal.pone.0089978.g001
Table 4. Incidences of severe acute respiratory virus infections among children aged <5 years in Matlab, Bangladesh, June–October 2010.

<table>
<thead>
<tr>
<th>Respiratory virus</th>
<th>Incidence (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;1 month</td>
</tr>
<tr>
<td>Total SARI</td>
<td></td>
</tr>
<tr>
<td></td>
<td>166.2 (66.8–342.3)</td>
</tr>
<tr>
<td>Hospitalized cases</td>
<td></td>
</tr>
<tr>
<td>RSV per 100,000 person-weeks (pw)</td>
<td>47.5 (5.8–171.5)</td>
</tr>
<tr>
<td>HPIV3 per 100,000 pw</td>
<td></td>
</tr>
<tr>
<td>Influenza per 100,000 pw</td>
<td>–</td>
</tr>
<tr>
<td>Influenza per 1,000 person-years (py)</td>
<td>–</td>
</tr>
<tr>
<td>Multiple viruses per 100,000 pw</td>
<td>–</td>
</tr>
<tr>
<td>Non-hospitalized cases</td>
<td></td>
</tr>
<tr>
<td>RSV per 100,000 pw</td>
<td>–</td>
</tr>
<tr>
<td>HPIV3 per 100,000 pw</td>
<td>–</td>
</tr>
<tr>
<td>Adenovirus per 100,000 pw</td>
<td>–</td>
</tr>
<tr>
<td>Influenza per 100,000 pw</td>
<td>–</td>
</tr>
<tr>
<td>Influenza per 1,000 py</td>
<td>–</td>
</tr>
<tr>
<td>Multiple viruses per 100,000 pw</td>
<td>–</td>
</tr>
</tbody>
</table>

doi:10.1371/journal.pone.0089978.t004
Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants

Maarten O. Blanken, M.D., Maroeska M. Rovers, Ph.D., Jorine M. Molenaar, M.D., Pauline L. Winkler-Seinstra, M.Sc., Adam Meijer, Ph.D., Jan L.L. Kimpen, M.D., Ph.D., and Louis Bont, M.D., Ph.D., for the Dutch RSV Neonatal Network

Table 1. Proportion of Infants with Proven Respiratory Syncytial Virus (RSV) Infection.*

<table>
<thead>
<tr>
<th>Variable</th>
<th>Palivizumab (N=214)</th>
<th>Placebo (N=215)</th>
<th>Absolute Risk Reduction†</th>
<th>Relative Risk Reduction (95% CI)‡</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total RSV infection</td>
<td>10 (4.7)</td>
<td>30 (14.0)</td>
<td>9.3</td>
<td>67 (27 to 107)</td>
<td>0.001</td>
</tr>
<tr>
<td>Hospitalization for RSV infection</td>
<td>2 (0.9)</td>
<td>11 (5.1)</td>
<td>4.2</td>
<td>82 (18 to 157)</td>
<td>0.01</td>
</tr>
<tr>
<td>Medically attended RSV infection without hospitalization</td>
<td>2 (0.9)</td>
<td>10 (4.7)</td>
<td>3.7</td>
<td>80 (11 to 161)</td>
<td>0.02</td>
</tr>
<tr>
<td>RSV infection without medical attention</td>
<td>6 (2.8)</td>
<td>9 (4.2)</td>
<td>1.4</td>
<td>33 (−56 to 126)</td>
<td>0.40</td>
</tr>
</tbody>
</table>

* Medical attention was registered during the home visits and reported by parents on the daily log.
† The absolute and relative values for risk reduction are for the palivizumab group as compared with the placebo group.
Figure 2. Cumulative Wheezing Days for 429 Preterm Infants during the First Year of Life.

P<0.001 for the comparison between palivizumab and placebo with the use of Poisson regression.
RSV Vaccine Snapshot

[Diagram showing various vaccine development phases and companies]

Source: http://sites.path.org/vaccinedevelopment/respiratory-syncytial-virus-rsv/

Updated: February 25, 2014
Barriers to RSV Vaccine Development

• Legacy of enhanced RSV disease by a killed RSV vaccine.
• Early age of first RSV infection
• Capacity of RSV to evade innate immunity
• Failure of RSV-induced adaptive immunity to prevent reinfection
• Lack of an animal model fully permissive to human RSV infection
Generating Live Attenuated RSV Vaccine Candidates

Figure 55-2: Schematic Representation (Not to scale) of the Mutations found in Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine Candidate Viruses (A) and in the Human Parainfluenza Virus 3 (HPIV3) Candidate Vaccine Virus cp45 (B). A, Mutations in the RSV genome are identified as point mutations (arrows) or as gene deletions (Δ). Point mutations are further identified as mutations induced by serial cold-passage (cp) or as temperature-sensitive (ts) mutations induced by chemical mutagenesis (identified numerically). The number assigned to the ts mutation indicates the clone number of the virus in which the mutation was first identified. B, The 15 mutations in cp45 that are thought to be important for conferring attenuation are identified at the site of the mutation (arrows). Those mutations that are known to produce virus that is cold adapted (ca), temperature-sensitive (ts), or attenuated in nonhuman primates (att) are indicated by the corresponding abbreviation.
Identification of a Recombinant Live Attenuated Respiratory Syncytial Virus Vaccine Candidate That Is Highly Attenuated in Infants

Ruth A. Karron,¹ Peter F. Wright,⁵ Robert B. Belshe,² Bhagvanji Thumar,¹ Roberta Casey,¹ Frances Newman,² Fernando P. Polack,¹ Valerie B. Randolph,⁴ Anne Deatly,⁴ Jill Hackell,⁴ William Gruber,⁴ Brian R. Murphy,² and Peter L. Collins²

<table>
<thead>
<tr>
<th>Participants, virus given</th>
<th>Dose, log₁₀ pfu</th>
<th>No. of participants</th>
<th>Participants infected, %</th>
<th>Participants who shed virus, %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infants</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rA2cp248/404/1030ΔSH</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>⁵ First dose</td>
<td>4.3</td>
<td>16</td>
<td>63</td>
<td>63</td>
</tr>
<tr>
<td>⁵ Second dose</td>
<td>4.3</td>
<td>14</td>
<td>29</td>
<td>29</td>
</tr>
<tr>
<td>rA2cp248/404/1030ΔSH</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>⁵ First dose</td>
<td>5.3</td>
<td>16</td>
<td>94</td>
<td>94</td>
</tr>
<tr>
<td>⁵ Second dose</td>
<td>5.3</td>
<td>16</td>
<td>44</td>
<td>44</td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>⁵ First dose</td>
<td>...</td>
<td>12</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>⁵ Second dose</td>
<td>...</td>
<td>9</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

The Journal of Infectious Diseases 2005;191:1093-104
### Chimeric Vaccines

**Phase 1 Study of the Safety and Immunogenicity of a Live, Attenuated Respiratory Syncytial Virus and Parainfluenza Virus Type 3 Vaccine in Seronegative Children**

David I. Bernstein, MD, MA,* Elissa Malkin, DO, MPH,† Nazha Abughali, MD,‡ Judith Falloon, MD,† Tingting Yi, PhD,† and Filip Dubovsky, MD, MPH,† for the MI-CP149 Investigators

#### TABLE 1. Seroresponse to RSV and PIV3 in Subjects Who Received the RSV/PIV3 Vaccine

<table>
<thead>
<tr>
<th></th>
<th>Cohort 1 (10^4 TCID&lt;sub&gt;50&lt;/sub&gt;)</th>
<th>Cohort 2 (10^5 TCID&lt;sub&gt;50&lt;/sub&gt;)</th>
<th>Cohort 3 (10^6 TCID&lt;sub&gt;50&lt;/sub&gt;)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N (%)</td>
<td>95% CI</td>
<td>n/N (%)</td>
</tr>
</tbody>
</table>
| RSV
Dose 1        | 2/11 (18.2) | 2.3–51.8   | 3/7 (42.9) | 9.9–81.6   | 4/9 (44.4) | 13.7–78.8   |
Dose 2        | 1/10 (10)   | 0.3–44.5   | 1/5 (20.0) | 0.5–71.6   | 5/9 (55.6) | 21.2–86.3   |
Dose 3        | 3/8 (37.5)  | 8.5–75.5   | 1/5 (20.0) | 0.5–71.6   | 4/8 (50.0) | 15.7–84.3   |
| PIV3
Dose 1        | 6/11 (54.5) | 23.4–83.3  | 5/7 (71.4) | 29.0–96.3  | 8/10 (80.0) | 44.4–97.5   |
Dose 2        | 6/10 (60.0) | 26.2–87.8  | 4/5 (80.0) | 28.4–99.5  | 7/9 (77.8) | 40.0–97.2   |
Dose 3        | 8/10 (80.0) | 44.4–97.5  | 3/5 (60.0) | 14.7–94.7  | 8/8 (100)  | 63.1–100    |

Seroresponse was defined as a ≥4-fold rise from baseline. Microneutralization assay (RSV) and HAI assay (PIV3) results were excluded from analysis upon demonstration of wild-type RSV/PIV3 shedding. For microneutralization assay analysis, a value of 2.5 was assigned if the result was below the LOQ (<5); and for HAI analysis, a value of 2 was assigned if the result was below the LOQ (<4).

CI indicates confidence interval; RSV, respiratory syncytial virus; PIV3, parainfluenza virus type 3; HAI, hemagglutination inhibition; LOQ, limit of quantification.

(Pediatr Infect Dis J 2012;31:109–114)
Absence of enhanced RSV disease after live, attenuated RSV vaccines

<table>
<thead>
<tr>
<th></th>
<th>Live attenuated RSV vaccine</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSV –Upper Resp Infect:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Vaccinated 1-3 mo age</td>
<td>15%</td>
<td>25% (VE 54%)</td>
</tr>
<tr>
<td>• Vaccinated 6-24 mo age</td>
<td>6.4%</td>
<td>15% (VE 40%)</td>
</tr>
<tr>
<td>RSV Sub Group A rate</td>
<td>8.6 / 100 ch-y</td>
<td>12.7 / 100 ch-y</td>
</tr>
<tr>
<td>RSV Sub Group B rate</td>
<td>4.6 / 100 ch-y</td>
<td>7 /100 ch-y</td>
</tr>
</tbody>
</table>

Wright PF et al. Vaccine 2007;25:7372-8

Wright PF et al. Vaccine 2007;25:7372-8
Subunit Vaccines: Advances in Understanding RSV F Protein Structure and Function

• RSV F glycoprotein mediates viral entry into host cells
• During cell entry: F undergoes a conformational change that brings viral and cellular membranes together, ultimately leading to fusion (Lamb, 2007)
• Activation of RSV F from pre-fusion state requires cleavage by furin at 2 sites, and a vast structural change in F conformation. (Gonzales-Reyes, PNAS 2001)
  • The structure of RSV protein in circulating virus and virus attached to cell surface differs remarkably (Swanson PNAS 2011)
  • Antigenic targets for pre and post fusion also differ
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

Kurt A. Swanson, Ethan C. Settembre, Christine A. Shaw, Antu K. Dey, Rino Rappuoli, Christian W. Mandl, Philip R. Dormitzer, and Andrea Carfì

Novartis Vaccines and Diagnostics, Cambridge, MA 02139

Fig. 1. RSV F ectodomain structure. (A) Linear diagram. Listed residue numbers correspond to the N terminus of each segment, the furin cleavage sites (arrowheads), and the C terminus. DI–III, domains I–III; p27, excised peptide; FP, fusion peptide; HRA, -B, and -C, heptad repeats A, B, and C. (B) Ribbon representation of one subunit. Domains colored as in A. Glycans are black. (C) Surface representation of the trimer. One subunit colored by domains as in A; the other two are white and gray.
Recombinant Nanoparticle Vaccine: Novavax

F Protein Gene → Insert into Baculovirus

Infect Sf9 Insect Cells

F Protein expressed BV/SF9 System

EM of Insect cell-derived RSV F nanoparticles

Trimers Form RSV F Nanoparticles

Impact of Maternal RSV Antibody on Hospitalizations

**TABLE I.** Titer of maternally derived RSV neutralizing antibodies and the incidence rate ratio of RSV hospitalization among children below 6 months of age; RSV hospitalized infants were compared with randomly selected infants

<table>
<thead>
<tr>
<th>Maternally derived RSV neutralizing antibodies titer</th>
<th>Birth to 5 mo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (Nsub)</td>
</tr>
<tr>
<td>0-6</td>
<td>48 (49)</td>
</tr>
<tr>
<td>6.5</td>
<td>25 (45)</td>
</tr>
<tr>
<td>7.0-7.5</td>
<td>57 (98)</td>
</tr>
<tr>
<td>8-8.5</td>
<td>35 (84)</td>
</tr>
<tr>
<td>9+</td>
<td>32 (118)</td>
</tr>
<tr>
<td>All</td>
<td>197 (394)</td>
</tr>
</tbody>
</table>

N, Number of cases; Nsub, number of children in subcohort.

*The estimates are adjusted for sex, premature birth, nonatopic chronic disease, maternal atopic dermatitis, maternal asthma, season, children below 12 years of age in the home (“siblings”), maternal smoking and occupation, and RSV seasonality.

†Test for trend when titers were analyzed as a continuous variable—that is, per 1 unit increase in titer.
RSV-A Neutralization antibodies in Cord Blood of newborns from mothers vaccinated in 3rd trimester of pregnancy with RSV purified fusion protein-2 vaccine

Increased RSV IgG antibodies in infants from women immunized with RSV purified fusion protein-2 vaccine

Conclusions

• A safe and effective RSV vaccine is needed for low and middle income countries in the world.
• Maternal immunization needs further exploration
• Infants need to receive 1\textsuperscript{st} vaccine dose below or at 10w of age to receive maximum benefit.
• Vaccine study outcomes:
  — RSV-associated severe ALRI
  — Recurrent wheeze
Problems that need further research

• Fear of enhanced severity or RSV disease by RSV vaccines (not clear why inactivated RSV vaccines produced this effect).
• Is there mortality associated with severe wheeze in developing countries? Are all classified as pneumonia?
• How to deal with mixed infections detected by sensitive PCR diagnostic tools?
• How to separate symptomatic from asymptomatic RSV infected infants?
• Are infants with poor immune response to RSV vaccine protected? How to measure functional antibody response.
• Will maternal immunization interfere infant immunization?
• No new vaccines have been licensed for pregnant women: licensing pathway may be complicated!
Thanks!

PATH:
• Deborah Higgins
• Cheryl Keech

WHO:
• Vasseharan Sathiyamoorthy

Vanderbilt:
• Kathryn Edwards